Melatonin and Metformin Failed to Modify the Effect of Dacarbazine in Melanoma.
Dacarbazine
Melanoma
Melatonin
Metformin
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
01
11
2020
accepted:
09
03
2021
pubmed:
23
3
2021
medline:
6
7
2021
entrez:
22
3
2021
Statut:
ppublish
Résumé
Melatonin did not increase the efficacy of systemic chemotherapy in melanoma. Metformin did not increase the efficacy of systemic chemotherapy in melanoma. Current data support the possibility of antitumor activity of melatonin and metformin. From March 2014 to December 2016, 57 patients with disseminated melanoma received dacarbazine (DTIC) 1,000 mg/m ORR was 7% and did not differ among the treatment groups. Median TTP was 57, 57, and 47 days, respectively, in the first, second, and third groups (р = .362). Median OS was 236, 422, and 419 days, respectively (p = .712). Two patients from the combinations groups showed delayed response to therapy. The increase of CD3 No benefit was found in either combination over DTIC monotherapy. Delayed responses in melatonin and metformin combination groups were registered. The increase of lymphocyte subpopulations responsible for antitumor immune response demonstrates the immune system's potential involvement in clinical activity.
Sections du résumé
LESSONS LEARNED
Melatonin did not increase the efficacy of systemic chemotherapy in melanoma. Metformin did not increase the efficacy of systemic chemotherapy in melanoma.
BACKGROUND
Current data support the possibility of antitumor activity of melatonin and metformin.
METHODS
From March 2014 to December 2016, 57 patients with disseminated melanoma received dacarbazine (DTIC) 1,000 mg/m
RESULTS
ORR was 7% and did not differ among the treatment groups. Median TTP was 57, 57, and 47 days, respectively, in the first, second, and third groups (р = .362). Median OS was 236, 422, and 419 days, respectively (p = .712). Two patients from the combinations groups showed delayed response to therapy. The increase of CD3
CONCLUSION
No benefit was found in either combination over DTIC monotherapy. Delayed responses in melatonin and metformin combination groups were registered. The increase of lymphocyte subpopulations responsible for antitumor immune response demonstrates the immune system's potential involvement in clinical activity.
Identifiants
pubmed: 33749049
doi: 10.1002/onco.13761
pmc: PMC8100566
doi:
Substances chimiques
Dacarbazine
7GR28W0FJI
Metformin
9100L32L2N
Melatonin
JL5DK93RCL
Banques de données
ClinicalTrials.gov
['NCT02190838']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
364-e734Informations de copyright
© AlphaMed Press; the data published online to support this summary is the property of the authors.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Br J Cancer. 1994 Jan;69(1):196-9
pubmed: 8286206
In Vivo. 2002 Mar-Apr;16(2):93-6
pubmed: 12073777
Integr Cancer Ther. 2012 Dec;11(4):293-303
pubmed: 22019490
J Clin Oncol. 2009 Nov 20;27(33):e207-9; author reply e210
pubmed: 19858375
Cell Cycle. 2012 Mar 1;11(5):865-70
pubmed: 22333588
Altern Med Rev. 2003 Aug;8(3):223-46
pubmed: 12946237
PLoS One. 2013 Aug 02;8(8):e71583
pubmed: 23936520
Melanoma Res. 1991 Nov-Dec;1(4):237-43
pubmed: 1823632
Int J Exp Pathol. 2006 Apr;87(2):81-7
pubmed: 16623752
Clin Cancer Res. 2012 May 15;18(10):2723-5
pubmed: 22465829
J Diabetes. 2011 Dec;3(4):320-7
pubmed: 21631893
Cancer Treat Rev. 2017 Mar;54:34-42
pubmed: 28189914
Cancer Prev Res (Phila). 2020 Sep 21;:
pubmed: 32958585
Oncogene. 2013 Mar 21;32(12):1475-87
pubmed: 22665053
Clin Cancer Res. 2010 May 1;16(9):2505-11
pubmed: 20388847
J Pineal Res. 1996 Nov;21(4):239-42
pubmed: 8989723
Invest New Drugs. 2012 Apr;30(2):647-52
pubmed: 20978924
Clin Cancer Res. 2012 Jan 1;18(1):40-50
pubmed: 22215905
Oncotarget. 2011 Dec;2(12):896-917
pubmed: 22203527
Cancer Res. 2007 Jul 15;67(14):6745-52
pubmed: 17638885
Ann Oncol. 2011 Dec;22(12):2556-2560
pubmed: 21421541
Ann Oncol. 2010 Jan;21(1):187-9
pubmed: 19884247